Marble Harbor Investment Counsel LLC Has $19.51 Million Stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Marble Harbor Investment Counsel LLC reduced its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 0.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 40,049 shares of the company’s stock after selling 50 shares during the quarter. IDEXX Laboratories makes up approximately 2.3% of Marble Harbor Investment Counsel LLC’s portfolio, making the stock its 11th largest position. Marble Harbor Investment Counsel LLC’s holdings in IDEXX Laboratories were worth $19,512,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Rathbones Group PLC increased its position in IDEXX Laboratories by 21.2% in the 2nd quarter. Rathbones Group PLC now owns 97,235 shares of the company’s stock worth $47,373,000 after purchasing an additional 16,975 shares during the last quarter. Lyell Wealth Management LP increased its holdings in IDEXX Laboratories by 4.3% in the second quarter. Lyell Wealth Management LP now owns 21,139 shares of the company’s stock worth $10,299,000 after buying an additional 868 shares during the last quarter. J.W. Cole Advisors Inc. bought a new position in IDEXX Laboratories during the second quarter valued at approximately $649,000. Envestnet Asset Management Inc. raised its position in IDEXX Laboratories by 6.7% during the second quarter. Envestnet Asset Management Inc. now owns 216,220 shares of the company’s stock valued at $105,342,000 after acquiring an additional 13,532 shares in the last quarter. Finally, Oppenheimer Asset Management Inc. lifted its stake in IDEXX Laboratories by 13.8% in the second quarter. Oppenheimer Asset Management Inc. now owns 11,957 shares of the company’s stock valued at $5,825,000 after acquiring an additional 1,453 shares during the last quarter. 87.84% of the stock is owned by hedge funds and other institutional investors.

IDEXX Laboratories Trading Up 0.7 %

NASDAQ:IDXX opened at $500.55 on Monday. The business’s 50-day simple moving average is $481.18 and its 200-day simple moving average is $500.72. IDEXX Laboratories, Inc. has a fifty-two week low of $372.50 and a fifty-two week high of $583.39. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.37 and a quick ratio of 1.03. The stock has a market capitalization of $41.34 billion, a PE ratio of 48.46, a price-to-earnings-growth ratio of 4.17 and a beta of 1.33.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Tuesday, August 6th. The company reported $2.44 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.88 by ($0.44). The firm had revenue of $1 billion during the quarter, compared to analyst estimates of $1.01 billion. IDEXX Laboratories had a net margin of 22.34% and a return on equity of 57.03%. The business’s revenue for the quarter was up 6.4% compared to the same quarter last year. During the same period in the prior year, the business earned $2.67 EPS. Sell-side analysts expect that IDEXX Laboratories, Inc. will post 10.45 earnings per share for the current fiscal year.

Analysts Set New Price Targets

IDXX has been the topic of a number of recent research reports. BTIG Research assumed coverage on shares of IDEXX Laboratories in a report on Thursday, July 25th. They set a “buy” rating and a $580.00 price target on the stock. Stifel Nicolaus reduced their price target on IDEXX Laboratories from $520.00 to $510.00 and set a “hold” rating for the company in a research report on Monday, June 24th. StockNews.com downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, July 10th. Finally, Piper Sandler decreased their price target on shares of IDEXX Laboratories from $600.00 to $520.00 and set a “neutral” rating on the stock in a research report on Wednesday, August 14th. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $582.25.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.